Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Caldas, C. & Tannock, I. F. Breast cancer: Tamoxifen–when more might be better. Nat Rev Clin Oncol 10, 125–126,
https://doi.org/10.1038/nrclinonc.2013.17
(2013).
2. Goetz, M. P., Kamal, A. & Ames, M. M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83, 160–166,
https://doi.org/10.1038/sj.clpt.6100367
(2008).
3. Stearns, V. & Rae, J. M. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 10, e34,
https://doi.org/10.1017/S1462399408000896
(2008).
4. Borgna, J. L. & Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. The Journal of biological chemistry 256, 859–868 (1981).
5. Jordan, V. C., Collins, M. M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75, 305–316 (1977).